AREV NanoTec Brands Inc. announces that the Company has entered into a collaborative development agreement with Voynich Biosciences, Inc. that further advances AREV's initiative, the next-generation Ready-to-Use Therapeutic Food ("RUTF"), SUS-TAINNTM. Voynich is an early-stage, privately-held, phytomedicinal discovery company headquartered in Hawaii and strategically located to facilitate collaboration with the National Tropical Botanical Garden and with laboratory operations adjacent to the Linus Pauling Institute ("LPI") of Oregon State University ("OSU"). AREV, in collaboration with Voynich, will be pursuing definitive partnerships with government and non-governmental organizations to ensure the successful delivery of SUS-TAINN to the most seriously affected areas. The RUTF market was valued at USD $363.72 Million in 2019 and is projected to reach $807.89 Million by 2027, growing at a CAGR of 10.5% from 2020 to 2027 according to a recent UNICEF report on RUTFs. The collaborative agreement between AREV and Voynich enhances an existing cooperative effort for tangible innovation in combating global food insecurity and nutritional deficits leading to Severe Acute Malnutrition ("SAM") and starvation, clinically defined as inanition, particularly among vulnerable populations presenting co-morbid conditions and co-infections.